A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Clinical trial NCT04505826 · COMPLETED

Trial details

NCT number: NCT04505826
Sponsor: Olema Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hormone Receptor Positive Breast Carcinoma HER2-negative Breast Cancer

Start date: 2020-08-13
Primary completion: 2024-07-30
Enrollment: 153

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.